scholarly journals Comment on Rosenstock et al. Impact of a Weekly Glucagon-Like Peptide 1 Receptor Agonist, Albiglutide, on Glycemic Control and on Reducing Prandial Insulin Use in Type 2 Diabetes Inadequately Controlled on Multiple Insulin Therapy: A Randomized Trial. Diabetes Care 2020;43:2509–2518

Diabetes Care ◽  
2021 ◽  
Vol 44 (11) ◽  
pp. e194-e195 ◽  
Author(s):  
Chinmay S. Marathe ◽  
Karen L. Jones ◽  
Christopher K. Rayner ◽  
Tongzhi Wu ◽  
Michael Horowitz
Keyword(s):  
Type 2 Diabetes ◽  
Glycemic Control ◽  
Insulin Therapy ◽  
Randomized Trial ◽  
Diabetes Care ◽  
Receptor Agonist ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Insulin Use

scholarly journals A practical Guide to Treatment with Liraglutide

2010 ◽  
Vol 2 ◽  
pp. CMT.S4148 ◽  
Author(s):  
Devasenan Devendra ◽  
Vassiliki Bravis
Keyword(s):  
Blood Pressure ◽  
Type 2 Diabetes ◽  
Body Weight ◽  
Glycemic Control ◽  
Receptor Agonist ◽  
Efficacy And Safety ◽  
Once Daily ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

Liraglutide–-a once-daily human glucagon-like peptide-1 receptor agonist for treatment of Type 2 diabetes–-provides effective glycemic control with a lower incidence of hypoglycemia than therapies such as glimepiride and exenatide, and reduces body weight and systolic blood pressure. This article briefly discusses efficacy and safety results from the Liraglutide Effect and Action in Diabetes (LEAD) program, before considering practical issues of identifying and educating patients who may be suitable for liraglutide therapy.

Sign in / Sign up

Export Citation Format

Share Document